Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD)
By Education For Health, PRNE
November 17th, 2009
New Report Highlights Global Economic Burden of the Disease
LONDON, November 18 - COPD Uncovered, a new report issued today reveals for the first time that
people between the ages of 40 to 65 are emerging as the new face of this
disease. Authored by Education for Health and other leading experts, the
report uncovers a new, younger majority of COPD patients(1) who are in the
prime of their career, and financially responsible for the care of their
children and aging parents. The authors call for policymakers to read the
report and challenge their thinking on how COPD should be addressed in this
critical age group who are highly depended upon by society as leading wage
earners(2,3).
COPD affects 210 million people and is predicted to be the third leading
cause of death globally in ten years time(4). A severely debilitating
disease, COPD dramatically impairs the productivity of this population. In
fact, the report found that people between 40 and 65 with COPD miss as many
as ten hours of work per week because of their condition(5). On a global
scale, that represents more than two billion working hours lost each week
worldwide. Additionally, COPD causes nearly 28,000 years of lost productivity
annually(6). The report deduces that if left unchecked, COPD could have
significant global workforce and economic implications on patients, families,
employers and society as the disease escalates.
"Given the potential economic impact, it is critical that 40 to 65 year
olds with COPD are able to lead an active and productive life," said Monica
Fletcher, Chief Executive of Education for Health. "In releasing this report
we want to spark an important global dialogue with key global stakeholders on
how best to invest in earlier diagnosis and the management of these younger
patients."
Other key insights from the report include:
- COPD costs more than asthma and diabetes - The cost of COPD
exceeds that of many other serious, long-term conditions including
asthma and diabetes(7). The worldwide burden of COPD is nearly double
that of diabetes and it causes more deaths(6).
- Effective COPD treatment must look beyond smoking cessation - It is
true that the primary cause of COPD is cigarette smoke(8) and smoking
cessation is an important part of COPD management. Yet many former
smokers develop symptoms and are diagnosed a decade or two after they
stopped. In fact, even if all smoking stopped today, the effect on COPD
statistics would not be seen for up to 20 years(9).
- COPD puts pressure on healthcare systems - One in six
European and U.S. patients had visited the ER or hospital in a six
month period 2006-20075. Extrapolating these figures indicates that up
to 64 million COPD patients globally may be admitted to hospital due to
their condition each year. Additionally, a large majority of COPD
patients suffer from co-morbidities, such as heart disease, high blood
pressure and diabetes(10-13). In fact, 40 percent suffer from heart
disease10 and as many as 42 percent from high blood pressure(12,13).
- Families may also face burden - More women than men are now being
be diagnosed with COPD(14) - a patient segment central to family care.
About COPD
Chronic obstructive pulmonary disease (COPD) is a debilitating,
life-threatening and progressive lung disease that interferes with normal
breathing(8). It is thought to cause around three million deaths per year -
on average one person every 10 seconds(4). COPD refers to emphysema and
chronic bronchitis - two commonly co-existing diseases of the lung. Due to
lung deterioration, people with COPD experience symptoms like chronic
shortness of breath and cough that impact the ability to lead an active and
productive life(8). There is no cure for COPD but it can be treated.
About COPD Uncovered
COPD Uncovered represents the combined efforts of a multi-disciplinary
committee of international experts, coming together to bring forward some of
the most burning issues in COPD today. Their aim is to highlight the impact
of COPD in an understudied and ignored patient segment between the ages of 40
and 65.
The COPD Uncovered initiative is a compendium of research and analysis
undertaken by experts in respiratory health. This initiative is sponsored by
Novartis Pharma AG and is administered by a Secretariat from Chandler Chicco
Companies (CCC). The studies underlying the COPD Uncovered Report were
commissioned by Novartis Pharma AG.
Following the release of this report, the COPD Uncovered experts are
conducting further quantitative research into the direct and indirect costs
of the disease among this age group. In 2010, they expect to release the
results of the study that will look at the specific impact of COPD on the
daily lives of more than 2,000 COPD patients aged 45-67 from the U.S., the
UK, Germany, Brazil, China and Turkey.
About the Authors
The COPD Uncovered Report, issued on World COPD Day 2009, is authored by
the following individuals, supported by Novartis with editorial assistance
from medical education specialists from CCC:
- Monica Fletcher, Chief Executive, Education for Health and National
Respiratory Training Center, principle lead for COPD Uncovered
- Dr Marianella Salapatas, President, European Federation of Allergy and
Airways Diseases Patients' Associations
- Professor Thys van der Molen, Department of General Practice,
University of Groningen
- John Walsh, President and CEO, COPD Foundation
To download a copy of the COPD Uncovered report, visit:
bit.ly/3n99Yu
References:
www.educationforhealth.org.uk/pages/_documents/COPD_Release.pdf
For press enquiries, please contact:
Sue Davis Russell - PA to Chief Executive
Education for Health
Tel: +44-(0)1926-836841, Email: s.davisrussell@educationforhealth.org
Candy Perry - Head of Corporate Communications and External Affairs
Education for Health
Tel: +44-(0)1926-836995, Email: c.perry@educationforhealth.org
Visit our website at: www.educationforhealth.org
For press enquiries, please contact: Sue Davis Russell - PA to Chief Executive Education for Health, Tel: +44-(0)1926-836841, Email: s.davisrussell at educationforhealth.org. Candy Perry - Head of Corporate Communications and External Affairs, Education for Health, Tel: +44-(0)1926-836995, Email: c.perry at educationforhealth.org
Filed under Biotechnology, Business, Health, Health Care / Hospitals, Pharmaceuticals, Surveys / Polls / Research | Tags: Education For Health, London, United Kingdom | Comment Below
Related Press Releases Data From Largest GOLD Stage II Patient Population Treated With Tiotropium Highlight the Benefits of Earlier Treatment of COPDAugust 27th, 2009 INGELHEIM, Germany -
- New UPLIFT(R) Analysis Shows Tiotropium Significantly Improves Lung Function and Quality of Life in COPD Patients With Early Stage Disease
- Not for US Media
A new analysis of the landmark UPLIFT(R) trial, published today in the Lancet, shows that tiotropium (SPIRIVA(R) Handihaler(R) 18 micro g) administered to Chronic Obstructive Pulmonary Disease (COPD) patients with moderate disease severity (GOLD - Global Initiative for Chronic Obstructive Lung Disease - Stage II) produced significant and sustained improvements in lung function for up to 4 years.[1] This pre-specified subgroup analysis involved 2,739 patients - the largest group of early stage COPD patients treated with a long-acting anticholinergic in a randomised, placebo-controlled study. The new UPLIFT(R) analysis shows that in patients with GOLD Stage II COPD, tiotropium may slow the progression of COPD as measured by the rate of decline in lung function. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 AuctionAugust 17th, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461August 17th, 2009 SAN DIEGO -
Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory DiseasesJune 29th, 2009 SAN DIEGO -
- Results Demonstrate Positive Proof of Mechanism
Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research ConferenceJune 14th, 2009 SAN DIEGO - Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona. Chiesi Creates New Research Centre to Study Innovative Therapies for the Treatment of Respiratory and Special Care DiseasesJune 11th, 2009 PARMA, Italy - The centre, which is to be located in Parma over an area of 22,000 sq. m., will be operative from 2011 and will employ over 300 qualified researchers from both Italy and abroad. WHO and EFA Call for Global Action on Chronic Respiratory DiseaseJune 10th, 2009 ROME - Call to Reduce the Four Million Deaths Annually, From a Condition Responsible for More Fatalities Globally Than AIDS[1]
The World Health Organisation (WHO) and European Federation of Allergy and Airways Diseases (EFA) today announced that they are bringing together over 150 international delegates to discuss the growing epidemic of Chronic Respiratory Diseases (CRD) that affects one billion people worldwide[1,2,3] and is responsible for four million deaths annually[1]. The conference which will discuss the implementation of a five-year initiative to unite policy makers, providers and patient groups will be hosted by the Italian Ministry of Health in Rome on June 12 and 13. Phase III Data Show Novartis Investigational Bronchodilator QAB149 Significantly Improves Lung Function Over Current Treatments in COPD[1,2]May 20th, 2009 BASEL, Switzerland - **This press release is not intended for the UK media**
- Once daily QAB149 (indacaterol) significantly improves lung function compared to formoterol and tiotropium, two currently approved COPD treatments, at three months of treatment[1,2] - Pending approval, QAB149 could be the first once-daily bronchodilator to combine clinically relevant 24-hour bronchodilation with onset of action within five minutes[3,4,5] - All doses of QAB149 are well-tolerated with a good overall safety profile in three pivotal trials: INVOLVE (1 year), INHANCE (6 months) and INLIGHT-1 (3 months)[4,5,6] - COPD, a debilitating and progressive respiratory disease, is a leading and growing cause of death that affects 210 million people worldwide[7]
BASEL, Switzerland, May 21 /PRNewswire/ --
Initial results from three pivotal phase III trials show the Novartis investigational bronchodilator QAB149 (indacaterol) could deliver clinically relevant[*] lung function improvements, within five minutes of the first dose, lasting for 24 hours in patients with chronic obstructive pulmonary disease (COPD)[3,4,5]. The data presented at the American Thoracic Society (ATS) 2009 International Conference in San Diego show that QAB149, a long-acting beta2-agonist (LABA), significantly improved lung function from the first day of therapy to up to one year of treatment1. Budesonide/Formoterol Plus Tiotropium Improves the Quality of Life of Patients With Severe COPDMay 20th, 2009 LUTON, England - News Release for the Medical Media
Preliminary results from a double-blind, randomised, multicentre trial among 660 patients with chronic obstructive pulmonary disease (COPD) show that budesonide/formoterol (Symbicort(R): AstraZeneca) plus tiotropium (Spiriva(TM): Boehringer Ingelheim Limited) significantly improves disease control and patients' quality of life (1,2). To view the Multimedia News Release, please click: www.prnewswire.com/mnr/astrazeneca/38533/
The study known as CLIMB, compared 12 weeks treatment with budesonide/formoterol (400/12 mcg one inhalation twice-daily) plus tiotropium (18 micro g one inhalation once daily) vs. Amira Initiates Phase I Clinical Trial of Novel DP2 AntagonistApril 19th, 2009 SAN DIEGO - Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD
Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway. AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
Related News Chronic diseases linked to higher levels of depressionJanuary 15th, 2009 WASHINGTON - People with chronic obstructive pulmonary disease (COPD) are nearly twice as likely to be depressed as diabetics. Dutch researchers compared the health characteristics of 999 patients with COPD, 978 patients with diabetes, and 2,494 healthy control subjects. Severe COPD linked to cognitive impairmentJuly 8th, 2009 WASHINGTON - A new study by researchers at Mount Sinai School of Medicine has shown that severe chronic obstructive pulmonary disease (COPD) is associated with lower cognitive function in older adults. COPD is caused by noxious particles or gas, most commonly from smoking, which trigger an abnormal inflammatory response in the lung. Action plan to phase out consumption of HCFC is on track: RameshSeptember 16th, 2009 NEW DELHI - Union Environment and Forest Minister Jairam Ramesh said on Wednesday that India has developed a comprehensive Road Map and Action Plan to phase-out of production and consumption of Hydrochlorofluorocarbons (HCFCs) in various sectors. Addressing the gathering during the 15th International Ozone Day here Ramesh said: "The Government of India has taken a number of policy measures, fiscal and regulatory, to encourage the early adoption of alternative technologies in this area by existing and new enterprises."
Ramesh hailed the Montreal Protocol as the most successful international treaty to ever achieve universal participation. Jaipur fire: Blaze slowly abating, area around site to open for nearby factory ownersNovember 2nd, 2009 JAIPUR - The fire at the Indian Oil depot in Jaipur, which started on October 29, is slowly abating and the area around 700-800 meters away from the site will be open for the factory owners to assess losses, District Magistrate of Jaipur Kuldeep Ranka said on Monday. "Fire in four tankers of Indian Oil Depots is still there. Long-term ozone exposure linked to higher death riskMarch 12th, 2009 WASHINGTON - Long-term exposure to ground-level ozone, a component of smog, may result in increased risk of death from respiratory ailments, according to a new study throughout the US. Ozone, a gas made up of three oxygen atoms - forms a protective layer from the sun's ultraviolet radiation when located in the Earth's upper atmosphere. Highlights from report on smoking in the militaryAugust 29th, 2009 A look at smoking in the militaryHighlights of a study commissioned by the Pentagon and the Veterans Affairs Department to combat tobacco use in the military. Findings:
— Tobacco is used by fewer than 20 percent of Americans compared with more than 30 percent of active-duty military personnel and about 22 percent of veterans. Costa Rica's health minister confirms swine flu death _ the first in Central AmericaMay 9th, 2009 Costa Rica confirms 1st swine flu deathSAN JOSE, Costa Rica — Costa Rica's health minister confirmed the death of a 53-year-old patient with swine flu on Saturday, the first death from the epidemic outside of a North American nation. The man, who also had diabetes and chronic lung disease, was one of eight swine flu cases in the Central American country that have been confirmed by the U.S. US talent firm to develop global workforce in IndiaApril 24th, 2009 BANGALORE - US-based talent management firm Global Crosswalk Inc (GCI), co-founded by two Indian expatriates, has set shop in India's IT hub to help companies develop global workforce for providing value-added/knowledge-based services. 'We offer niche solutions in cross-cultural strategies, culture competence and expatriate services to Indian and overseas firms operating in a globalised world,' GCI co-founder and chief executive Radha Nath told reporters here Friday. Costa Rica's health minister confirms swine flu death _ the first in Central AmericaMay 9th, 2009 Costa Rica confirms its 1st swine flu deathSAN JOSE, Costa Rica — Costa Rica's health minister confirmed the death of a 53-year-old patient with swine flu on Saturday, the first death from the pandemic outside of a North American nation. The man, who also had diabetes and chronic lung disease, was one of eight swine flu cases in the Central American country that have been confirmed by the U.S. Chrysler Financial cuts 9 percent of workforce, closes service centerJune 30th, 2009 Chrysler Financial to cut 9 percent of workforceDETROIT — Chrysler's former financial arm says it will reduce its workforce by 9 percent as it restructures and closes a customer service center in Overland Park, Kansas. Chrysler Financial, a company separate from Chrysler Group, says the moves come as it no longer serves as the automaker's preferred lender for financing Chrysler vehicle purchases and dealer inventories.
|
|